How Eloralintide Affects HbA1c

HbA1c reflects average glucose exposure over roughly the preceding three months, weighted toward the most recent weeks. Eloralintide lowers it through two routes that both reduce the area under the daily glucose curve.

The direct route is amylin signalling: suppressed meal-induced glucagon and slowed gastric emptying flatten the postprandial peak that contributes disproportionately to glycation.

The indirect route is fat loss, and at the magnitudes eloralintide produces this is probably the larger contributor over a 48 week horizon. Visceral fat reduction improves hepatic insulin sensitivity, which lowers fasting and postprandial glucose together.

HbA1c was a secondary endpoint in the Phase 2 trial (Billings et al., 2025). The pooled evidence for the amylin class comes largely from pramlintide, where a meta-analysis of ten randomised trials in type 1 diabetes found significant HbA1c reduction against placebo (Qiao et al., 2017).

Normal baseline (under 5.7 percent): minimal change. There is little glycation burden to remove, and a reading that barely moves is not a sign the drug is failing.

Elevated baseline (5.7 to 6.4 percent): a meaningful reduction is plausible over 12 to 24 weeks, driven mostly by the weight loss.

Timing: HbA1c lags. Do not repeat it before 8 weeks, and prefer 12, because a shorter interval mostly measures noise.

Confounder worth knowing: HbA1c is distorted by anything that changes red cell lifespan. Elevated haematocrit from androgen use, recent blood donation, or iron deficiency all shift it. In an enhanced athlete this matters, and fructosamine is the alternative when red cell turnover is in question.

Baseline before the first dose, paired with fasting glucose and fasting insulin.

Repeat at 12 weeks. Earlier repeats waste a test.

Use fructosamine instead if you have significantly elevated haematocrit, have donated blood recently, or have iron studies suggesting deficiency. Fructosamine reflects roughly two to three weeks of glucose exposure and is not affected by red cell lifespan.

Interpret alongside HOMA-IR. HbA1c tells you about average exposure. HOMA-IR tells you what your pancreas is doing to achieve it. A normal HbA1c on a high fasting insulin is a very different picture from a normal HbA1c on a low one.

If HbA1c does not move on a normal baseline: nothing is wrong. Track fasting insulin and HOMA-IR instead, where the change usually shows first and largest.

If HbA1c rises during a cut: look for a confounder before blaming the compound. Rising haematocrit on testosterone, dehydration, or a recent change in training load can all move it. Recheck with fructosamine.

If you are also running growth hormone or MK-677: those raise glucose and insulin resistance in the opposite direction, and the two effects can mask each other. Track both, and read the full picture rather than a single marker. See GH and insulin resistance.

Further reading: Does Eloralintide Protect Muscle Better Than a GLP-1?